An observational study in Repeatedly Recurring Esophagitis and Relapsing Reflux Esophagitis, sponsored by AstraZeneca. Completed at 46 sites in Japan. Per ClinicalTrials.gov, last updated 2014-10-31.
Sponsored by AstraZeneca · Observational
The purpose of this study is to collect following data in patients given Nexium capsule (Nexium) in usual post-marketing use as the maintenance therapy for repeatedly recurring/relapsing reflux oesophagitis.
Nexium capsules Specific Clinical Experience Investigation for Maintenance Therapy for Repeatedly Recurring/Relapsing Reflux Oesophagitis
322 studies on the registry are indexed under Esophagitis; 37 are open to participants now.
This study's enrollment of 647 is above the median of 100 across 91 observational studies indexed under Esophagitis.
Browse Esophagitis studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients with repeatedly recurring/relapsing reflux oesophagitis who will be given Nexium for the first time as a maintenance therapy.
(Patients who had been given Nexium for the initial treatment for reflux oesophagitis can be enrolled to this investigation).
Exclusion Criteria:
Number of Adverse Drug Reactions
Adverse event incidence
Time frame: 6 Month
Non-recurrence rate of reflux oesophagitis
Time frame: 6 Month
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca